Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacityChy-Anh Tran, Luciana Burton, Diana Russom, et al.Journal of Immunological Methods|July 1, 2005
A quantitative high-throughput chemotaxis assay using bioluminescent reporter cellsReena P Vishwanath, Christine E Brown, Jamie R Wagner, et al.Journal of Immunological Methods|March 22, 2005
Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killingChristine E Brown, Christine L Wright, Araceli Naranjo, et al.Blood Advances|September 7, 2021
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaTanya Siddiqi, Xiuli Wang, M Suzette Blanchard, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory ProgramSylvia O Dulan, Kathie L Viers, Jamie R Wagner, et al.Science Translational Medicine|January 20, 2017
Reporter gene imaging of targeted T cell immunotherapy in recurrent gliomaKhun Visith Keu, Timothy H Witney, Shahriar Yaghoubi, et al.Cell Reports. Medicine|August 16, 2025
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safetyMichael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, et al.The New England Journal of Medicine|December 29, 2016
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E Brown, Darya Alizadeh, Renate Starr, et al.Cell Stem Cell|March 12, 2022
3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cellsZhiqiang Wang, Helen P McWilliams-Koeppen, Hernan Reza, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALLIbrahim Aldoss, Samer K Khaled, Xiuli Wang, et al.Pageof 2